drugset / Trial / NCT03225846
Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease
RandomizedSequentialDouble-blindTreatment
Summary
PRECISION-HD2 is a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of WVE-120102 in adult patients with early manifest Huntington's disease (HD) who carry a targeted single nucleotide polymorphism (SNP) rs362331 (SNP2).
Timeline
- Start
- 2017-07-17
- Primary completion
- 2021-05-10
- Completion
- 2021-05-10
Outcome
Outcome not reported
Stopped: “Lack of efficacy”
Publications
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LEXANERSEN | Antisense oligonucleotide | 2 mg | Intrathecal |
| Subject | LEXANERSEN | Antisense oligonucleotide | 4 mg | Intrathecal |
| Subject | LEXANERSEN | Antisense oligonucleotide | 8 mg | Intrathecal |
| Subject | LEXANERSEN | Antisense oligonucleotide | 16 mg | Intrathecal |
| Subject | LEXANERSEN | Antisense oligonucleotide | 32 mg | Intrathecal |